Whitehawk Therapeutics (NASDAQ:WHWK) CEO David James Lennon Sells 102,395 Shares

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) CEO David James Lennon sold 102,395 shares of the firm’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $3.51, for a total value of $359,406.45. Following the completion of the transaction, the chief executive officer owned 691,154 shares of the company’s stock, valued at approximately $2,425,950.54. The trade was a 12.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David James Lennon also recently made the following trade(s):

• On Wednesday, April 8th, David James Lennon sold 63,945 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.40, for a total value of $217,413.00.
• On Tuesday, April 7th, David James Lennon sold 94,087 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.43, for a total value of $322,718.41.
• On Thursday, April 2nd, David James Lennon sold 26,858 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.48, for a total value of $93,465.84.
• On Monday, March 2nd, David James Lennon sold 5,100 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.31, for a total value of $16,881.00.

Whitehawk Therapeutics Stock Down 0.6%

WHWK opened at $3.41 on Thursday. The stock has a market cap of $160.95 million, a PE ratio of 7.26 and a beta of 0.57. The business has a 50 day moving average of $3.32 and a 200-day moving average of $2.69. Whitehawk Therapeutics, Inc. has a 52 week low of $1.39 and a 52 week high of $4.48.

Whitehawk Therapeutics (NASDAQ:WHWK) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.21.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Oppenheimer assumed coverage on Whitehawk Therapeutics in a research report on Thursday, February 5th. They set an “outperform” rating and a $6.00 price objective for the company. Wall Street Zen raised Whitehawk Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research report on Friday, March 27th. Finally, JonesTrading assumed coverage on Whitehawk Therapeutics in a report on Monday, December 22nd. They issued a “buy” rating and a $7.00 target price for the company. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $6.50.

Institutional Trading of Whitehawk Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Quadrature Capital Ltd purchased a new position in shares of Whitehawk Therapeutics in the 4th quarter worth $28,000. ABG Innovation Capital Partners III GP Ltd purchased a new position in shares of Whitehawk Therapeutics in the 3rd quarter worth $51,000. Geode Capital Management LLC boosted its stake in shares of Whitehawk Therapeutics by 11.4% in the 4th quarter. Geode Capital Management LLC now owns 425,440 shares of the company’s stock worth $1,030,000 after buying an additional 43,686 shares during the last quarter. Dimensional Fund Advisors LP purchased a new position in shares of Whitehawk Therapeutics in the 3rd quarter worth $84,000. Finally, Jane Street Group LLC boosted its stake in shares of Whitehawk Therapeutics by 177.3% in the 4th quarter. Jane Street Group LLC now owns 69,931 shares of the company’s stock worth $169,000 after buying an additional 44,716 shares during the last quarter. Institutional investors own 52.08% of the company’s stock.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.